Research progress of ALK kinase domain drug resistance mutation and its future countermeasures
Anaplastic lymphoma kinase (ALK) is one of the common oncogenic driver genes in non-small cell lung cancer (NSCLC).Tyrosine kinase inhibitors (TKIs) have achieved excellent therapeutic effects in patients with ALK fusion positive NSCLC.However, patients will eventually develop resistance to TKIs.Acquired molecular drug resistance mechanisms, such a